This subject comes up a lot in patient groups. The heterogeneity of Neuroendocrine Neoplasms (a term for both well differentiated NET and poorly differentiated NEC) tends to be forgotten as people start to make blanket statements as if it applies to every single NET patient. It becomes a rather circular discussion where certain readers might even be unnecessarily misled about their outcome casually suggested by someone who knows nothing about their diagnostic and treatment history. Part of the problem is the official cancer terms built in the 1970s remain in use today, but they do not fit the vast changes that have occurred in cancer survival and treatment for incurable types. Consequently, specialists are generating new and informal terms, more individualised, when passing on updates to their patients. Some non-official or informal terms are just synonyms of published and universally accepted terms but are provided with more context to bring it up to date.
Cure
I once wrote an article called “Neuroendocrine Cancer – can it be cured“. In that article, I covered the fact that most stage IV cancers (all cancers) are generally considered incurable, but I also added my own view of NETs being treatable in the same way a chronic disease would be. At the other end of the scale, I covered guidelines where doctors talk about removing tumours with “curative intent”, clearly in reference to small localized tumour scenarios. I’m pretty sure in my own mind that this does happen. As one example you only need to look at the epidemiology data on (say) small low-grade low-stage appendiceal and rectal NETs; to know that they rarely metastasise/recur, translated into guidelines as needing “no follow up” related to size and margin pathology score. However, in one sentence, “cure” generally means that there are no traces of your cancer after treatment and cancer will never come back. That’s a pretty big statement that seems impossible to predict in every single cancer patient. I guess doctors tread carefully before saying the word ‘cured‘. Epidemiology data plays a big part in decisions on how to guide doctors and manage patient expectations, i.e. based on the data collected over a period of years, doctors are able to assess the likelihood of a recurrence (as inferred above). For some doctors, I suspect they also base this on what they see in their own practices, at least in the larger hospitals seeing hundreds or thousands of patients over a period of time. When I read comments from members of my patient group, the lack of a standard is obvious. Words such as “stable“, “no evidence of disease” and “cancer free” are frequently used. Less quoted are terms such as “remission” or “cured“. I myself am “reassuringly stable” with “no evidence of progressive disease“.
What does remission actually mean?
I looked at various sources and they all appear to say the same thing. Most sites you find will say something like this extract below, although I have added informed comments from one of my ‘Go To’ physician sources where there is always context rather than the bland statements from national cancer organisations:
Remission means that the signs and symptoms of your cancer are reduced. Remission can be partial or complete.
- Partial remission means the cancer is still there, but your tumour has gotten smaller, or you have less cancer throughout your body. Some doctors tell patients to think of their cancer as “chronic,” (author’s note: and this is relevant to locally advanced or metastatic Neuroendocrine Tumours (NETs). It’s something you may need to continue to check. If you’re in partial remission, it may mean you can take a break from treatment (where applicable) as long as the cancer doesn’t begin to grow again.
- Complete remission means that tests, physical exams, and scans show that all signs of your cancer are gone. Some doctors also refer to complete remission as “no evidence of disease (NED).” However, that doesn’t mean you are cured. Doctors can only make these statements based on their imaging (i.e. what can be seen by imaging) or suggested by other tests. But there is still a chance that cancer will come back later. For this reason, doctors cannot say for sure that you are cured. The most they can say is that there are no signs of cancer at this time (e.g. “No evidence of disease”).
If you remain in complete remission for 5 years* or more, some doctors may discharge you saying you are “cured” but I suspect they mean ‘unlikely to return’ as cancers that return, most do so within the first 5 years after treatment. In scenarios where there is a higher chance of recurrence, your doctor may monitor you for many years and do tests to look for signs of cancer’s return. Hopefully, in that time, they will also look for signs of late side effects from the cancer treatments you received (an area that perhaps needs more attention?). Another synonym is “cancer free” but that needs added context.
*Interest point. As an indication that words are becoming more personalised, some cancer types have smaller or larger remission checkpoints due to known behaviours collected over the long term. Most NET guidelines state 10 years minimum for surveillance, and then clinical judgement after that. When I got 10 years, my surveillance intervals were changed to 1 year (e.g. my CT scan was extended from 6 months to 12 months due to ‘stable disease’. I’m just one example of a Stage IV grade 2 small intestine NET diagnosed in 2010 but with ‘evidence of indolent remnant disease’).
Recurrence
I think it’s worth including this definition as it overlaps with the remission definitions. Some cancer cells can remain unnoticed in the body for years after treatment. If cancer returns after it has been in remission, it’s called a “recurrence.” Cancer can recur in the same place it was originally diagnosed, or it can recur in a different part of the body. It’s normal to be concerned that this will happen to you. Every situation is different, and there’s no way to predict what will happen.
Summary
For some in the Neuroendocrine patient community, this is both a controversial and emotional subject, understandably so. However, it is not helped by the ‘blanket statements’ continually made about all types of Neuroendocrine Cancer (Neoplasms) when they only really apply to a subset. Neuroendocrine Neoplasms are a heterogenous collection of cancers and this heterogeneity applies in various other ways, not just in the classification of the disease. Some group owners need to look at how they moderate these often-circular discussions. Some people introduce the subject of “micrometastases” which in some cases might be scary to some people causing totally unnecessary anxiety. Just because micrometastases can’t be seen, does not mean they are actually there. NET specialists should have a handle on which type of NET are more likely to recur than others although this is very individualised. The remission and stable definitions above apply regardless.
Other than the general cancer definitions I’ve quoted below, there is no real standard for what a doctor should say to a patient at relevant points in their surveillance in terms of the future, this really is not an exact science. I believe it has to be understood that this is really pretty much the way things are and thus why words need to be carefully thought through before being uttered.
But whatever is said to a patient, these words are really important, as is the context in which they are said. Consequently, it’s important to ask the oncologist or specialist specifically what they mean. Because one doctor may use any of them one way, and another doctor might use them in another context.
I personally think for those with more advanced Neuroendocrine Cancers (i.e. higher stages), as long as you continue to get surveillance, access to therapy (without insurance-based constraints where this is applicable), these terms then become less significant.
Thanks for listening.
On the Cancer Journey, don’t forget to live your life – Ronny Allan – Living with Neuroendocrine Cancer

Disclaimer
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Thanks for reading.
Click here and answer all questions to join my private Facebook group
Facebook – Neuroendocrine Cancer
X (twitter) – Ronny Allan
Website
Instagram
Ronny
Check out my WEGO Health Awards
Check out my Glossary of Terms – click here
- Spotlight on Thymic Neuroendocrine Neoplasms (Thymic NENs)Disclaimer:The information in this Spotlight is for general education and awareness. It does not replace personalised medical advice, diagnosis, or treatment. Thymic Neuroendocrine Neoplasms (NENs) are complex and highly variable, and individual cases may differ significantly from the patterns described here. Always discuss your own situation, test results, and treatment options with your specialist team,… Read more: Spotlight on Thymic Neuroendocrine Neoplasms (Thymic NENs)
- An unmissable update from Ronny Allan covering April 2026A monthly update not to miss……..Summary of April 2026 on RonnyAllan.NET I think the main story of April is similar to March which was a strong blog performance. Some of March was so popular that it has rolled into April and I have tried to beat those figures but failed due to external pressures. Nonetheless, the… Read more: An unmissable update from Ronny Allan covering April 2026
- Spotlight on Small intestine Neuroendocrine Neoplasms (siNENs)DisclaimerThis Spotlight is for general education and reassurance only. It cannot replace personalised advice from your own medical team, who understand your individual history, imaging, pathology, and treatment needs. Neuroendocrine tumours vary widely in behaviour, presentation, and management, and guidance may evolve as new evidence emerges. If you have questions about your diagnosis, symptoms, or… Read more: Spotlight on Small intestine Neuroendocrine Neoplasms (siNENs)
- A Spotlight on Pancreatic Neuroendocrine NeoplasmsDisclaimerThe information in this Spotlight is for general education only. It cannot replace advice from your own medical team, who know your individual situation, test results, and treatment options. Neuroendocrine Neoplasms and related conditions are complex and research is evolving; guidance, classifications, and statistics may change over time. Always discuss any questions or concerns with… Read more: A Spotlight on Pancreatic Neuroendocrine Neoplasms
- Neuroendocrine Cancer in UK – a growing crisis?I was delighted to read about the efforts of Dr Arthur Scott, a Member of the UK Parliament (MP). He is a great advocate for cancer patients and recently introduced a rare cancer bill in the UK Parliament which will hopefully make a difference. The content was very interesting and I was drawn to several… Read more: Neuroendocrine Cancer in UK – a growing crisis?
- Bone Metastases in Well‑Differentiated NETs – Part 2 – TreatmentDisclaimerThis information is for education and reassurance only.It is not a substitute for personalised medical advice, diagnosis, or treatment. Bone metastases in neuroendocrine tumours (NETs) vary widely in behaviour, appearance, and clinical significance. Decisions about systemic therapy, radiotherapy, ablation, bone‑targeted agents, surgery, or monitoring must be made by your own specialist NET team, who understand… Read more: Bone Metastases in Well‑Differentiated NETs – Part 2 – Treatment
- Neuroendocrine Tumours – Vitamin B3 (Niacin)Before you read thisThis information is designed to help you understand how vitamins work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely. If you have concerns… Read more: Neuroendocrine Tumours – Vitamin B3 (Niacin)
- March 2026 Newsletter from Ronny AllanHere is my monthly summary of March 2026 on RonnyAllan.NET This has been a very good month but to be honest, I had more time at home and on my computer, due to illness. OK I was not that ill that I could not tap away at a keyboard! However, it was pretty erratic access. I… Read more: March 2026 Newsletter from Ronny Allan
- Understanding Differentiation, Ki‑67, Mitotic Count, Hotspots, Pathology Workflow, and Primary–Metastasis Heterogeneity in Neuroendocrine Neoplasms (NENs)Before you read this… This article discusses pathology concepts such as Ki-67, grading, heterogeneity, and biopsy findings in neuroendocrine tumours (NETs). It is provided for educational purposes only and does not interpret any individual pathology report or scan result. Ki-67 values, tumour grade, and sampling limitations can vary between different biopsies and over time. Their… Read more: Understanding Differentiation, Ki‑67, Mitotic Count, Hotspots, Pathology Workflow, and Primary–Metastasis Heterogeneity in Neuroendocrine Neoplasms (NENs)
- Why liver transplant is back in the NET conversationBefore you read this… This article is provided to support understanding of a complex and evolving topic. It explains how liver transplant is being explored in a very small number of NET patients, but it is not suggesting that this treatment is suitable for you or anyone else. Every NET case is unique. Only your… Read more: Why liver transplant is back in the NET conversation
- This too shall passIf you’ve heard that phrase before, you’re not alone. The phrase is rooted in older Persian and Buddhist teachings, and widely accepted as a testament to the impermanence of all things. Many famous people have used this phrase including Abraham Lincoln, Tom Hanks, Robert De Niro and King Solomon. I’ve also seen various cancer bloggers… Read more: This too shall pass
- HRT and Neuroendocrine Tumours (NETs): What Patients Need to KnowBefore you read this… This article discusses hormone replacement therapy (HRT) in the context of general health, menopause, and neuroendocrine tumours (NETs). It is provided for educational purposes only and does not recommend starting, stopping, or changing any form of HRT. The suitability of HRT depends on many individual factors, including tumour type, grade, hormone… Read more: HRT and Neuroendocrine Tumours (NETs): What Patients Need to Know
- Blood Clot risks in Neuroendocrine Neoplasms (NENs)I have a personal interest in this subject because I had pulmonary emboli (PE) diagnosed in January 2011 around 6 weeks after I had major surgery. I got a phone call from the hospital to go down that day and meet with a nurse who would teach me to self inject ‘Clexane'(Enoxaparin) and then take… Read more: Blood Clot risks in Neuroendocrine Neoplasms (NENs)
- Neuroendocrine Tumours (NETs) – Vitamin D (Cholecalciferol / Ergocalciferol)Before you read thisThis information is designed to help you understand how vitamins work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely.If you have concerns about… Read more: Neuroendocrine Tumours (NETs) – Vitamin D (Cholecalciferol / Ergocalciferol)
Discover more from Ronny Allan - Living with Neuroendocrine Cancer
Subscribe to get the latest posts sent to your email.


















Thanks for your writings!
I don’t like the term NED being applied to NET patients. I think the medical community should adopt the term NEAT–No Evidence of Active Tumors. I think NED is interpreted as you no longer have cancer. Wrong!
I get where you’re coming from. Personally I think the medical profession needs to come up with more modern terms for today’s cancer where people can live longer, even in a stable condition (stable means no change to disease status). I think “evidence” is the word that we need to focus on, so if any test is not finding “evidence” of disease, then doctors just can’t assume or guess that it is still there. However, they do have experience of treating people who have had recurrence so I guess that drives a surveillance regime to follow. Statistics play a part in that and due to the heterogenous nature of NET, clearly risks are higher or lower depending on which type of NET they deal with. My own oncologist described by status as “no evidence of progressive disease”, my interpretation of that is that they can see something they consider to be disease but it has not really changed since the last scan or series of scans.